Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
| 대상 질환 | Smoldering Plasma Cell Myeloma |
|---|---|
| 임상 단계 | 초기 1상 |
| 스폰서 | M.D. Anderson Cancer Center |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 20 명 |
| 중재(약물) | Laboratory Biomarker Analysis, Pembrolizumab |
| 시작일 | 2016년 7월 20일 |
| 완료일 | 2017년 12월 30일 |
| 결과 공개일 | 2020년 3월 20일 |
요약
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Overall Response Rate (ORR)
| Treatment (Pembrolizumab) | 1 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (M — National Cancer Institute (NCI)